[Skip navigation]FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

Recall of Pegaspargase, Oncaspar


DATE RECALL INITIATED:

June 12, 2002

LOT NUMBERS / EXPIRATION DATE:

AK0129     11/1/2003
AA0201     1/1/2004
AE0114     5/1/2003
AE0115     5/1/2003
AH0120     8/1/2003

MANUFACTURER:

Enzon, Inc.
Piscataway, NJ

REASON:

The lots of Pegaspargase, Oncaspar, were recalled due to high-in-vitro enzymatic activity levels, above the label claim of 750 IU/ml +/- 20%. Additional testing was performed on all lots manufactured on or after February 13, 2002, to ensure they are currently within specification. Consignees have been asked to contact the manufacturer to arrange for product return.


The information in this listing reflects CBER's best efforts to communicate information that has been reported to FDA. Its accuracy and comprehensiveness cannot be guaranteed.


Last Updated: 7/25/2002

 

Back to Top     Back to Index

Updated: September 26, 2003

horizonal rule